as 07-08-2024 4:00pm EST
NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.
Founded: | N/A | Country: | Switzerland |
Employees: | 250 | City: | N/A |
Market Cap: | N/A | IPO Year: | 2021 |
Target Price: | N/A | AVG Volume (30 days): | N/A |
Analyst Decision: | N/A | Number of Analysts: | N/A |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | N/A | EPS Growth: | N/A |
52 Week Low/High: | N/A | Next Earning Date: | N/A |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
NLSPW Breaking Stock News: Dive into NLSPW Ticker-Specific Updates for Smart Investing
MT Newswires
10 days ago
ACCESSWIRE
10 days ago
MT Newswires
11 days ago
MT Newswires
11 days ago
ACCESSWIRE
11 days ago
ACCESSWIRE
13 days ago
ACCESSWIRE
a month ago
ACCESSWIRE
a month ago
The information presented on this page, "NLSPW NLS Pharmaceutics Ltd. Warrant - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.